Hørsholm, Denmark, September 3, 2020 - ExpreS2ion Biotech Holding AB ("ExpreS2ion") hereby announces that Aktiespararnars' Analysguiden has published an updated equity research report on ExpreS2ion. The updated sum-of-the-parts valuation base case is raised to 24 SEK per share after the completion of the proposed rights issue in October 2020 at 12 SEK per share.

The raised sum-of-the-parts valuation is primarily based on the progress in the PREVENT-nCoV Covid-19 vaccine program, with phase III clinical trials expected to start in H1 2021, and ExpreS[2]ion's recently announced decision to inlicense the AV001 breast cancer vaccine candicate from its joint venture AdaptVac.

The full English version of the company-sponsored equity research report is attached to this press release, while the Swedish version is available on Analysguiden's website: https://www.aktiespararna.se/analysguiden/nyheter/analys-expres2ion-stor-uppsida-med-minskad-risk

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: +46 11 32 30 732

E-post: ca@skmg.se

For further information about ExpreS[2]ion, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com

About ExpreS[2]ion

ExpreS[2]ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS[2]ion Biotech Holding AB with company register number 559033-3729. ExpreS[2]ion has developed a unique technology platform, ExpreS[2], for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS[2] is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS[2]ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.

https://news.cision.com/expres2ion-biotechnologies/r/analysguiden-raises-its-target-price-for-expres2ion-to-24-sek-per-share,c3188075

https://mb.cision.com/Main/14402/3188075/1301965.pdf

https://mb.cision.com/Public/14402/3188075/90e7bb0fff00b808.pdf

(c) 2020 Cision. All rights reserved., source Press Releases - English